Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 6/20 | 0.37 |
| ▸ | PAK4 | O96013 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | VNN1 | O95497 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19742295 | 0.93 | PAK4 (0.31) | GABRA5STAT3PAK4ATRPTK2 | |
| SCHEMBL17859423 | 0.86 | GABRA5 (0.41) | GABRA5STAT3PAK4HPGDRORC | |
| SCHEMBL19742272 | 0.86 | GABRA5 (0.37) | GABRA5STAT3PAK4ATRPTK2 | |
| SCHEMBL17859425 | 0.83 | PAK4 (0.41) | GABRA5STAT3PAK4HRH3 | |
| SCHEMBL17859426 | 0.83 | PAK4 (0.41) | GABRA5STAT3PAK4HRH3 | |
| SCHEMBL17859536 | 0.82 | PAK4 (0.42) | GABRA5STAT3PAK4HRH3 | |
| SCHEMBL17844699 | 0.82 | GABRA5 (0.39) | GABRA5STAT3PAK4ATRSFRP1 | |
| SCHEMBL17844723 | 0.82 | PAK4 (0.38) | GABRA5STAT3PAK4ATRPTK2 | |
| SCHEMBL18317597 | 0.82 | PAK4 (0.42) | GABRA5STAT3PAK4ATRHPGD | |
| SCHEMBL17844713 | 0.81 | PAK4 (0.43) | GABRA5STAT3PAK4PTK2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170369470-A1 | Cyclic Compounds and Uses Thereof | Karyopharm Therapeutics Inc. | 2017-12-28 | — | — | US | disclosed |
| WO-2016100515-A1 | CYCLIC COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369470-A1 | Cyclic Compounds and Uses Thereof | MALT1, BCL9, BCL6 | GABRA5 2240/4885STAT3 91/4885PAK4 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.